Promoter group entity Maxcell Communication India Private Limited has transferred 12,00,000 equity shares of Vivo Bio Tech Limited off-market on August 21, 2026. The transaction marks the complete exit of the promoter affiliate from the company, reducing its stake to nil.

The disclosure was filed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Gangireddy Suresh, Director at Maxcell Communication, signed the intimation submitted to the BSE and the listed entity.

Shareholding Changes

Prior to the transfer, Maxcell Communication held 12,00,000 equity shares, representing 5.41% of the total voting capital and 4.09% of the diluted voting capital. The entity had no encumbrances, warrants, or convertible securities associated with this holding.

Following the off-market transfer, the promoter group entity’s holding stands at Nil. There were no changes to the company’s total equity share capital or diluted share capital as a result of this inter-se transfer.

Capital Structure Context

Vivo Bio Tech’s total equity share capital remains at 2,21,90,628 equity shares of ₹10 each, aggregating to ₹22,19,06,280. The total diluted share capital is calculated at 2,93,23,111 equity shares. This diluted figure assumes the conversion of 6,27,409 pending convertible equity warrants and the exercise of 63,22,000 outstanding ESOPs.

What the Numbers Show

The complete divestment by a promoter group entity suggests a consolidation of holdings within the promoter circle or a strategic restructuring of interests. With Maxcell Communication exiting entirely, the voting power previously held by this specific entity is likely consolidated elsewhere within the promoter group, though the filing does not specify the recipient of the transferred shares.

Dwight Technologies Private Limited acquired a 5.41% stake in Vivo Bio Tech Limited through an off-market transaction on August 21, 2026.

The Hyderabad-based acquirer purchased 12,00,000 equity shares, bringing its total holding to 30,72,561 shares. This represents 13.85% of the company’s total voting capital and 10.48% of its diluted share capital.

Acquisition Details

The transaction was reported under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Dwight Technologies confirmed it does not belong to the promoter or promoter group of Vivo Bio Tech.

The equity share capital of Vivo Bio Tech remained unchanged at 2,21,90,628 shares, aggregating ₹22,19,06,280. The total diluted share capital stands at 2,93,23,111 shares, based on the assumption that pending convertible equity warrants and outstanding ESOPs will be exercised.

What the Numbers Show

The acquisition significantly consolidates Dwight Technologies’ position as a major shareholder. By increasing its stake from 8.44% to 13.85%, the entity has crossed the 10% threshold in voting capital, which often triggers additional disclosure obligations and signals a deeper strategic interest in the target company’s governance and direction.